American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Add to calender
Research

Wednesday, May 8, 2024 poster presentations:

P-705: “Robust and Durable RNA Editing In Vivo with Axiomer™ Editing Oligonucleotides in Non-Human Primates”

  • Building on its robust platform data, the Company will present additional non-human primate (NHP) data including with ACTB and NTCP and initial in vitro and in vivo preclinical proof of concept for its AX-0810 program targeting NTCP for cholestatic diseases, including hepatic editing in NHP with strong correlating impact on disease-relevant biomarkers.
     

P-726, partner poster presentation by Eli Lilly: “Complex Metabolism and Prolonged PK/PD of a GalNAc-Conjugated Editing Oligonucleotide (EON) in Mice”

Presentation_ProQR_Robust-and-Durable-RNA-Editing-In Vivo-with-Axiomer-Editing-Oligonucleotides-in-Non-Human-Primates_ASGCT2024

You might like this

  • Press releases

    Read the latest news on our development programs, business updates and announcements. You can sign up for email alerts so you stay up to date on all things ProQR.

    Female scientist working in ProQR's laboratories

  • Our science

    Our passion lies in discovering the latest RNA technologies and translating them to life-changing treatments for people with genetic diseases.

    Axiomer RNA editing platform technology

  • About ProQR Therapeutics

    ProQR was founded by Daniel de Boer with a mission to help people living with rare genetic diseases. This remains the sole focus of our company today.

    Daniel de Boer wearing a blue suit stands with arm crossed in a laboratory setting.